CustomCustomCustomCustomCustomCustom
9 01, 2025

TAmiRNA ‘2024 In Review’

2025-01-09T14:05:02+01:00January 9th, 2025|biomarker, Biomarker Discovery, biomarkers, CE-IVD, congress, EVscale, exosomes, extracellular vesicle, hepatomiR kit, Illumina NewSeq2000, ISO 13485, liquid biopsies, Liver disease, microRNA, microRNA services, microRNAs, NGS, PCR testing service, quality, sequencing, small RNA-sequencing, smallRNA, test service|Comments Off on TAmiRNA ‘2024 In Review’

2024: A Year of Growth, Innovation, and Collaboration 2024 has come to a close. We are proud to reflect on the milestones and achievements we’ve reached together with our incredible team, customers, partners, and supporters. Here’s a look back at what we accomplished this year: 👩‍🔬 Team Expansion Welcomed 3 talented new members to our growing team. 🏥 Diagnostic Implementation Successfully rolled out our CE-IVD microRNA liver function test in 5+ clinics, advancing molecular diagnostics. ✅ Service Excellence Completed over 80 RNA service projects, achieving 100% customer satisfaction. 🛠 Bioinformatics Innovation Developed 2 new pipelines: isomiR analysis and tRNA analysis, enhancing our capabilities. 🧬 Expanded Service Offerings Added whole-transcriptome sequencing for mRNA, lncRNA, and circRNA in liquid biopsies to our service portfolio. [...]

Read More
13 02, 2024

Webinar – COST Action AtheroNET

2024-02-13T11:20:12+01:00February 13th, 2024|biomarker, biomarkers, exosomes, extracellular vesicle, microRNA, microRNA services, microRNAs, quality, sequencing, smallRNA|Comments Off on Webinar – COST Action AtheroNET

Looking forward to sharing our insights from 10+ years of extracellular microRNA (and recently long RNA as well) biomarker discovery and diagnostic test development with the COST Action AtheroNET group. Date: 19.02.2024 Time: 19:30 CET Registration Link: https://lnkd.in/dVDDYKcA Reach out to Matthias directly after his webinar and discuss our latest developments and how TAmiRNA’s  miND spike ins and small RNA sequencing service can assist your business!

Read More
26 01, 2024

TAmiRNA ‘2023 In Review’

2024-01-26T11:44:38+01:00January 26th, 2024|biomarker, biomarkers, exosomes, extracellular vesicle, ISO 13485, Liver disease, microRNA, microRNA services, microRNAs, quality, sequencing, smallRNA|Comments Off on TAmiRNA ‘2023 In Review’

One last look back at 2023 before we turn our attention to our goals for 2024: last year brought us progress in many areas, from the development of new laboratory and data analyses to the implementation of hepatomiR® in routine clinical diagnostics and the establishment of important partnerships. Our thanks go to the entire (growing) TAmiRNA team, and our customers and partners! We look forward to working together and to our joint successes in 2024!

Read More
17 01, 2024

Analysis of extracellular vesicle microRNA profiles reveals distinct blood and lymphatic endothelial cell origins

2024-01-17T11:03:50+01:00January 17th, 2024|biomarker, biomarkers, exosomes, extracellular vesicle, microRNA, microRNA services, microRNAs|Comments Off on Analysis of extracellular vesicle microRNA profiles reveals distinct blood and lymphatic endothelial cell origins

We want to draw your attention to the latest collaborative publication by TAmiRNA scientist Marianne Pultar: “Analysis of extracellular vesicle microRNA profiles reveals distinct blood and lymphatic endothelial cell origins” published in the Journal of Extracellular Biology. By applying TAmiRNA´s unique small RNA-seq and RNA-seq workflows, this study provides important insights into the secretory behavior of endothelial cell-derived extracellular vesicles (EVs) and their microRNA cargo. In future, these findings can support the identification and development of non-invasive and cell-type specific biomarkers in liquid biopsis. Click here to learn more about our EV service click here to read the paper

Read More
10 01, 2024

TAmiRNA partners with Techtum Lab

2024-01-10T09:45:03+01:00January 10th, 2024|microRNA, microRNA services, microRNAs, miND spike ins, NGS, PCR testing service, smallRNA, Techtum Lab|Comments Off on TAmiRNA partners with Techtum Lab

TAmiRNA has entered an exclusive distribution agreement with Techtum Lab for the sales of their products in the Nordics. Techtum Lab is a full service supplier and partner to clinical and research molecular biology laboratories and looks back at >45 years of experience in the Nordic region. TAmiRNA complements Techtum’s NGS portfolio with the miND Spike-Ins, a unique set of controls for small RNA sequencing experiments. Furthermore, Techtum partners with TAmiRNA to make customized RNA sequencing services accessible to those customers who are looking for external support with analysing their sample’s RNA content.

Read More
22 11, 2023

TAmiRNA meets Japanese Pharma to present microRNA Biomarker Discovery Solutions

2023-11-22T11:22:16+01:00November 22nd, 2023|biomarker, biomarkers, exosomes, extracellular vesicle, microRNA, microRNA services, microRNAs, NGS, PCR testing service, SPI|Comments Off on TAmiRNA meets Japanese Pharma to present microRNA Biomarker Discovery Solutions

Matthias Hackl, CEO/CSO of TAmiRNA, visited Japan between November 11th and 18th to join Summit Pharmaceutical international to introduce TAmiRNA to 12 medium- and large-size pharmaceutical companies. Matthias presented information on microRNA and mRNA biomarker discovery in liquid biopsies using TAmiRNA´s unique miND® pipeline for absolute quantification of microRNAs. In addition, Matthias joined a seminar on “Manufacturing and omic-based characterization of extracellular vesicles as drug products” organized by the local partner Summit Pharmaceutical International. In his talk, Matthias explained to >70 representatives from Japanese Universities and Pharmaceutical industry TAmiRNA’s the advantages of full molecular characterization of exosomes and extracellular vesicles (EVs) to determine EV composition, consistency, and mode-of-action.

Read More
31 01, 2023

We are proud to announce our ISO 13485:2016 certification

2023-03-10T08:28:14+01:00January 31st, 2023|biomarkers, ISO 13485, microRNA, quality, smallRNA|Comments Off on We are proud to announce our ISO 13485:2016 certification

Today we announce that TAmiRNA has received ISO 13485:2016 certification for its Medical Device and Quality Management System after successfully completing the audit through Germany-based notified body MDC. This ISO certification indicates that TAmiRNAs quality management system meets the most current regulatory requirements applicable to the medical device industry. "We are very proud of this certification as it demonstrates the commitment of our team to meet customer and international regulatory expectations," said Matthias Hackl, Co-Founder and CEO of TAmiRNA. ISO 13485:2016 is an internationally recognized quality systems standard tailored to the development and manufacturing of medical devices, including in-vitro diagnostic tests. This certification represents an important milestone for our company, and reflects our rigorous and risk-based approach [...]

Read More
30 01, 2023

Plasma levels of platelet-enriched microRNAs change during antiplatelet therapy in healthy subjects

2023-03-10T08:28:49+01:00January 30th, 2023|biomarkers, diagnose disease, extracellular vesicle, microRNA, platelet-associated miRNAs, smallRNA, thrombomiR, treatment monitoring|Comments Off on Plasma levels of platelet-enriched microRNAs change during antiplatelet therapy in healthy subjects

We want to draw your attention to our most recent publication where we investigated platelet-enriched miRNAs (thrombomiRs) as suitable candidates for monitoring antiplatelet therapy. The study provides evidence that thrombomiRs are promising biomarker candidates for monitoring the extent of platelet inhibition. This could enable stratification of patients depending on their response to antiplatelet therapy and guide treatment decisions. click here to read the paper

Read More
17 01, 2023

Biogenity Joins Forces with TAmiRNA

2023-03-10T08:29:26+01:00January 17th, 2023|biomarkers, diagnose disease, microRNA, NGS, smallRNA, treatment monitoring|Comments Off on Biogenity Joins Forces with TAmiRNA

The collaboration between Biogenity and TAmiRNA is a big step towards further enabling our clients to identify new biomarkers that can be used to diagnose disease, monitor treatment response, and predict patient outcomes. And an important step to advance omics research and bring better healthcare to future generations. click here to read the press release

Read More
28 10, 2022

miND spike-in

2023-03-10T10:13:11+01:00October 28th, 2022|microRNA, NGS, smallRNA|Comments Off on miND spike-in

TAmiRNA has launched an innovative NGS technology for absolute quantitation of miRNAs and other small RNAs , the miND® (microRNA Next-Generation Sequencing Discovery) spike-in. The miND® spike-in has been developed for small RNA sequencing experiments and absolute quantitation of microRNAs in any biological matrix and species, overcoming previous challenges of quality control and difficulty in achieving  absolute quantitation of miRNAs across different biological matrix and species. click here for more Information on the miND spike-ins

Read More
© Copyright TAmiRNA 2019 - 
Go to Top